Zynerba Pharmaceuticals, Inc. (ZYNE): Price and Financial Metrics


Zynerba Pharmaceuticals, Inc. (ZYNE): $3.87

-0.26 (-6.30%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ZYNE Stock Summary

  • Zynerba Pharmaceuticals Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 7.07% of US listed stocks.
  • With a price/sales ratio of 1,661.62, Zynerba Pharmaceuticals Inc has a higher such ratio than 99.79% of stocks in our set.
  • The volatility of Zynerba Pharmaceuticals Inc's share price is greater than that of 93.47% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to Zynerba Pharmaceuticals Inc, a group of peers worth examining would be BPMX, RVNC, ADVM, PSTI, and PRTA.
  • Visit ZYNE's SEC page to see the company's official filings. To visit the company's web site, go to www.zynerba.com.

ZYNE Stock Price Chart Interactive Chart >

Price chart for ZYNE

ZYNE Price/Volume Stats

Current price $3.87 52-week high $9.00
Prev. close $4.13 52-week low $3.15
Day low $3.81 Volume 4,533,800
Day high $4.07 Avg. volume 2,777,749
50-day MA $4.19 Dividend yield N/A
200-day MA $4.58 Market Cap 159.65M

Zynerba Pharmaceuticals, Inc. (ZYNE) Company Bio


Zynerba Pharmaceuticals is a specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. The company was founded in 2007 and is based in Devon, Pennsylvania.


ZYNE Latest News Stream


Event/Time News Detail
Loading, please wait...

ZYNE Latest Social Stream


Loading social stream, please wait...

View Full ZYNE Social Stream

Latest ZYNE News From Around the Web

Below are the latest news stories about Zynerba Pharmaceuticals Inc that investors may wish to consider to help them evaluate ZYNE as an investment opportunity.

Zynerba Pharmaceuticals Announces Presentations at Two Upcoming Scientific Conferences in October

DEVON, Pa., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced oral and poster presentations at the Society for Developmental & Behavioral Pediatrics Annual Meeting, being held virtually October 21-25, 2021, and the 68th American Academy of Child & Adolescent Psychiatry Annual Meeting, being held virtually October 18-

Yahoo | October 21, 2021

Zynerba Pharmaceuticals Announces Presentation of Poster at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit

DEVON, Pa., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the presentation of a poster at the 2021 National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit being held virtually October 18-19, 2021. A copy of the poster titled, “RECONNECT (ZYN2-CL-033): Design of a Phas

Yahoo | October 19, 2021

Zynerba Pharmaceuticals Announces Presentation of Poster at the 2021 American Academy of Pediatrics National Conference & Exhibition

DEVON, Pa., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the presentation of a poster at the 2021 American Academy of Pediatrics (AAP) National Conference & Exhibition, which will be held virtually from October 8-11, 2021. A copy of the poster titled, “Longer Term Tolerability and Efficacy of ZYN002 Cannabidiol

Yahoo | October 8, 2021

Zynerba Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference

DEVON, Pa., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will participate in a fireside chat during the 2021 Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 11:20 a.m. ET.

Intrado Digital Media | September 20, 2021

Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel in Fragile X Syndrome - Zynerba

Trial will evaluate the efficacy and safety of Zygel in children and adolescents with Fragile X Syndrome Topline results expected in second half of 2023 DEVON, Pa., Sept. 13, 2021 (GLOBE NEWSWIRE) Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announces the initiation of []

Zynerba Pharmaceuticals | September 13, 2021

Read More 'ZYNE' Stories Here

ZYNE Price Returns

1-mo -14.57%
3-mo -14.19%
6-mo -14.00%
1-year 4.03%
3-year -32.70%
5-year -67.48%
YTD 17.27%
2020 -45.36%
2019 103.37%
2018 -76.28%
2017 -19.69%
2016 54.82%

Continue Researching ZYNE

Here are a few links from around the web to help you further your research on Zynerba Pharmaceuticals Inc's stock as an investment opportunity:

Zynerba Pharmaceuticals Inc (ZYNE) Stock Price | Nasdaq
Zynerba Pharmaceuticals Inc (ZYNE) Stock Quote, History and News - Yahoo Finance
Zynerba Pharmaceuticals Inc (ZYNE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7978 seconds.